Craif (Location: Bunkyo-ku, Tokyo, CEO: Ryuichi Onose, hereinafter referred to as “Craif”) and Institute Hospital of JFCR (Location: Koto-ku, Tokyo, Hospital Director: Takeshi Sano) have signed a joint research agreement. With the conclusion of this agreement, Craif and Breast Surgical Oncology Department (Department Director: Takayuki Ueno) at Institute Hospital of JFCR will begin a joint study to clarify the clinical significance of urinary miRNA in primary breast cancer for early detection of breast cancer, the evaluation of treatment efficacy, and the diagnosis of recurrence after treatment.
■Outline of Research
Until now, it was technically difficult to capture miRNAs efficiently in body fluids. Craif’s distinctive zinc oxide nanowire device makes it possible to efficiently capture and analyze urinary miRNAs. By applying this technique as a non-invasive diagnostic biomarker for cancer, miRNA is expected to be used for early detection of cancer, evaluation of treatment efficacy, and diagnosis of recurrence after treatment.
Currently, the changes and effects of miRNA expression patterns in breast cancer have not yet been elucidated.
In this study, we will investigate the clinical significance of urinary miRNAs in primary breast cancer by comparing the results of general clinical findings and basic histopathological findings in breast cancer.